104 related articles for article (PubMed ID: 23047898)
41. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M
Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931
[TBL] [Abstract][Full Text] [Related]
42. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.
Gharehbaghi K; Burgess GS; Collart FR; Litz-Jackson S; Huberman E; Jayaram HN; Boswell HS
Leukemia; 1994 Aug; 8(8):1257-63. PubMed ID: 7520100
[TBL] [Abstract][Full Text] [Related]
43. A novel 53 kDa protein complexed with P210bcr-abl in human chronic myelogenous leukemia cells.
Li WJ; Kloetzer WS; Arlinghaus RB
Oncogene; 1988 Jun; 2(6):559-66. PubMed ID: 3133627
[TBL] [Abstract][Full Text] [Related]
44. Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.
Cutler JA; Tahir R; Sreenivasamurthy SK; Mitchell C; Renuse S; Nirujogi RS; Patil AH; Heydarian M; Wong X; Wu X; Huang TC; Kim MS; Reddy KL; Pandey A
Leukemia; 2017 Jul; 31(7):1513-1524. PubMed ID: 28210003
[TBL] [Abstract][Full Text] [Related]
45. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells.
Gilkes DM; Xiang L; Lee SJ; Chaturvedi P; Hubbi ME; Wirtz D; Semenza GL
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):E384-93. PubMed ID: 24324133
[TBL] [Abstract][Full Text] [Related]
46. Emerging targets in drug discovery against neurodegenerative diseases: Control of synapsis disfunction by the RhoA/ROCK pathway.
Martín-Cámara O; Cores Á; López-Alvarado P; Menéndez JC
Eur J Med Chem; 2021 Dec; 225():113742. PubMed ID: 34388381
[TBL] [Abstract][Full Text] [Related]
47. Metastasis of aggressive amoeboid sarcoma cells is dependent on Rho/ROCK/MLC signaling.
Kosla J; Paňková D; Plachý J; Tolde O; Bicanová K; Dvořák M; Rösel D; Brábek J
Cell Commun Signal; 2013 Jul; 11():51. PubMed ID: 23899007
[TBL] [Abstract][Full Text] [Related]
48. Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.
Pietrovito L; Comito G; Parri M; Giannoni E; Chiarugi P; Taddei ML
Curr Cancer Drug Targets; 2019; 19(10):807-816. PubMed ID: 30648509
[TBL] [Abstract][Full Text] [Related]
49. Matrix-bound PAI-1 supports cell blebbing via RhoA/ROCK1 signaling.
Cartier-Michaud A; Malo M; Charrière-Bertrand C; Gadea G; Anguille C; Supiramaniam A; Lesne A; Delaplace F; Hutzler G; Roux P; Lawrence DA; Barlovatz-Meimon G
PLoS One; 2012; 7(2):e32204. PubMed ID: 22363817
[TBL] [Abstract][Full Text] [Related]
50. The cleaved FAS ligand activates the Na(+)/H(+) exchanger NHE1 through Akt/ROCK1 to stimulate cell motility.
Monet M; Poët M; Tauzin S; Fouqué A; Cophignon A; Lagadic-Gossmann D; Vacher P; Legembre P; Counillon L
Sci Rep; 2016 Jun; 6():28008. PubMed ID: 27302366
[TBL] [Abstract][Full Text] [Related]
51. Hypoxia promotes tumor cell motility via RhoA and ROCK1 signaling pathways.
Leong HS; Chambers AF
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):887-8. PubMed ID: 24398519
[No Abstract] [Full Text] [Related]
52. Reduced WNT5A signaling in melanoma cells favors an amoeboid mode of invasion.
Jobe NP; Åsberg L; Andersson T
Mol Oncol; 2021 Jul; 15(7):1835-1848. PubMed ID: 33969605
[TBL] [Abstract][Full Text] [Related]
53. The three-way switch operation of Rac1/RhoA GTPase-based circuit controlling amoeboid-hybrid-mesenchymal transition.
Huang B; Lu M; Jolly MK; Tsarfaty I; Onuchic J; Ben-Jacob E
Sci Rep; 2014 Sep; 4():6449. PubMed ID: 25245029
[TBL] [Abstract][Full Text] [Related]
54. Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer.
Brown M; Roulson JA; Hart CA; Tawadros T; Clarke NW
Br J Cancer; 2014 Apr; 110(8):2099-108. PubMed ID: 24595005
[TBL] [Abstract][Full Text] [Related]
55. MMP inhibitor Ilomastat induced amoeboid-like motility via activation of the Rho signaling pathway in glioblastoma cells.
Yan S; Xue H; Zhang P; Han X; Guo X; Yuan G; Deng L; Li G
Tumour Biol; 2016 Oct; ():. PubMed ID: 27743382
[TBL] [Abstract][Full Text] [Related]
56. Cancer-associated fibroblasts as cellular vehicles in endometrial cancer cell migration.
Voon YC; Omar IS; Wu MH; Said NABM; Chung I
Oncol Lett; 2022 Jan; 23(1):3. PubMed ID: 34820002
[TBL] [Abstract][Full Text] [Related]
57. RhoA-ROCK competes with YAP to regulate amoeboid breast cancer cell migration in response to lymphatic-like flow.
Mohammadalipour A; Diaz MF; Livingston M; Ewere A; Zhou A; Horton PD; Olamigoke LT; Lamar JM; Hagan JP; Lee HJ; Wenzel PL
FASEB Bioadv; 2022 May; 4(5):342-361. PubMed ID: 35520391
[TBL] [Abstract][Full Text] [Related]
58. ROCK1 and LIMK2 interact in spread but not blebbing cancer cells.
Shea KF; Wells CM; Garner AP; Jones GE
PLoS One; 2008; 3(10):e3398. PubMed ID: 18852895
[TBL] [Abstract][Full Text] [Related]
59. A computational study of amoeboid motility in 3D: the role of extracellular matrix geometry, cell deformability, and cell-matrix adhesion.
Campbell EJ; Bagchi P
Biomech Model Mechanobiol; 2021 Feb; 20(1):167-191. PubMed ID: 32772275
[TBL] [Abstract][Full Text] [Related]
60. Identification of Cofilin-1 and Destrin as Potential Early-warning Biomarkers for Gamma Radiation in Mouse Liver Tissues.
Yi L; Hu N; Mu H; Sun J; Yin J; Dai K; Xu F; Yang N; Ding D
Health Phys; 2019 Jun; 116(6):749-759. PubMed ID: 30913056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
